UI Hospitals and Clinics

Clinical Trial Details

Short Title
Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab (TCHP) With or Without Estrogen Deprivation
Official Title
  A Randomized Phase III Trial Evaluating Pathologic Complete Response Rates in Patients with Hormone Receptor-Positive, HER2-Positive, Large Operable and Locally Advanced Breast Cancer Treated with Neoadjuvant Therapy of Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab (TCHP) With or Without Estrogen Deprivation
Description

Participants in this research study have breast cancer that is HER2-positive and is sensitive to hormones. The purpose of this research study is to compare the good and bad effects of using hormone drugs with the usual chemotherapy drugs to using the chemotherapy drugs alone as therapy given before surgery.

Approximately 7 people will take part in this treatment study conducted by investigators at the University of Iowa. There will be about 212 people taking part in this study nationally.

Start Date
May 2, 2014
End Date
January 1, 2017
Gender Preference
Female
Age Group
18 - 99 years
Principal Investigator
Alexandra Thomas, MD
Contact Info

Pamela Zehr      319-353-8914

Department
Hematology/Oncology
Keywords
Enter keyword ;

We welcome your feedback! Please help us improve your experience on our website by completing a brief survey.